Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anoro versus placebo in smokers at risk of early COPD
ACTRN12616001208493Phase 4Terminated
- Sponsor
- The George Institute for Global Health
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vilanterol and umeclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: FEV1 (post-bronchodilator) change from baseline to month 6. Started Dec 2016; status: terminated.
02
Drugs
vilanterolumeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12616001208493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001208493.